Shire Inks $325M Deal For Blood Disorder Drug Co.

Law360, New York (March 15, 2012, 2:12 PM EDT) -- Irish pharmaceutical power Shire PLC beefed up its blood disorder treatment division Thursday with a $325 million deal to acquire privately held California-based FerroKin BioSciences Inc., which specializes in drugs that treat iron overload.

Shire will plunk down $100 million in cash up front, plus up to $225 million in milestone payments tied to clinical development, regulatory and net sales targets, according to a statement the company issued Thursday.

The deal is part of Shire's push to grow its hematology business, which already includes platelet-reducer Xagrid....
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.